Conservest Capital Advisors Inc. purchased a new stake in Clovis Oncology Inc (NASDAQ:CLVS) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 3,697 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.
Several other large investors have also modified their holdings of CLVS. State Street Corp boosted its stake in shares of Clovis Oncology by 93.7% in the fourth quarter. State Street Corp now owns 2,141,663 shares of the biopharmaceutical company’s stock valued at $95,131,000 after buying an additional 1,035,917 shares in the last quarter. Consonance Capital Management LP boosted its stake in shares of Clovis Oncology by 20.3% in the third quarter. Consonance Capital Management LP now owns 3,531,487 shares of the biopharmaceutical company’s stock valued at $127,310,000 after buying an additional 595,000 shares in the last quarter. Norges Bank acquired a new stake in shares of Clovis Oncology during the fourth quarter valued at approximately $13,155,000. Teachers Advisors LLC boosted its stake in shares of Clovis Oncology by 153.9% in the fourth quarter. Teachers Advisors LLC now owns 420,512 shares of the biopharmaceutical company’s stock valued at $18,679,000 after buying an additional 254,898 shares in the last quarter. Finally, Iguana Healthcare Management LLC boosted its stake in shares of Clovis Oncology by 261.1% in the third quarter. Iguana Healthcare Management LLC now owns 325,000 shares of the biopharmaceutical company’s stock valued at $11,716,000 after buying an additional 235,000 shares in the last quarter. Institutional investors own 88.48% of the company’s stock.
Shares of Clovis Oncology Inc (NASDAQ:CLVS) traded down 4.37% on Friday, reaching $52.24. 1,947,522 shares of the company’s stock were exchanged. The stock’s market cap is $2.34 billion. Clovis Oncology Inc has a 52-week low of $11.57 and a 52-week high of $74.94. The company’s 50 day moving average price is $54.41 and its 200-day moving average price is $51.75.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million for the quarter, compared to analyst estimates of $6.04 million. Equities analysts forecast that Clovis Oncology Inc will post ($4.95) EPS for the current fiscal year.
CLVS has been the subject of several analyst reports. Chardan Capital reiterated a “sell” rating and set a $36.00 price target on shares of Clovis Oncology in a research report on Thursday, March 16th. JPMorgan Chase & Co. restated a “hold” rating on shares of Clovis Oncology in a report on Wednesday, March 15th. Credit Suisse Group AG restated an “outperform” rating and set a $74.00 price objective on shares of Clovis Oncology in a report on Tuesday, April 18th. Piper Jaffray Companies set a $77.00 price objective on shares of Clovis Oncology and gave the company a “buy” rating in a report on Tuesday, March 28th. Finally, Morgan Stanley restated an “overweight” rating and set a $79.00 price objective on shares of Clovis Oncology in a report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $60.79.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $56.02, for a total transaction of $168,060.00. Following the completion of the sale, the insider now owns 206,583 shares of the company’s stock, valued at approximately $11,572,779.66. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 9,000 shares of company stock valued at $511,200. Insiders own 17.40% of the company’s stock.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.